为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

2-(二苯基氨基)-N-[7-(羟基氨基)-7-氧代庚基]-5-嘧啶甲酰胺, 组蛋白去乙酰化酶 6 抑制剂

规格或纯度: ≥98%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
A124886-5mg
5mg 现货 Stock Image
A124886-10mg
10mg 现货 Stock Image
A124886-50mg
50mg 现货 Stock Image
A124886-100mg
100mg 现货 Stock Image

基本描述

英文别名 1316214-52-4|Ricolinostat|ACY-1215|Rocilinostat|2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide|Rocilinostat (ACY-1215)|ACY-63|Ricolinostat (ACY-1215)|N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide|
规格或纯度 ≥98%
英文名称 Rocilinostat (ACY-1215)
生化机理

ACY-1215 is an orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. ACY-1215 selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system throμgh hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth. HDAC6, a class II HDAC deacetylase located in the cytoplasm, appears to play a key role in the formation and activation of the aggresomes needed for degradation of misfolded proteins. Compared to non-selective HDAC inhibitor, ACY-1215 is able to reduce the toxic effects on normal, healthy cells.

储存温度 -20°C储存
运输条件 超低温冰袋运输
产品介绍

Rocilinostat (ACY-1215)是一种选择性HDAC6抑制剂, IC50为5 nM,作用于HDAC6比作用于HDAC1/2/3(I型HDACs)选择性高10倍以上,对HDAC8具有微弱的作用活性,对HDAC4/5/7/9/11, Sirtuin1和Sirtuin2具有最低限度的作用活性。

Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM. It is >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2.

产品属性

ALogP 3.4

名称和标识符

PubChem SID 488201578
PubChem SID url https://pubchem.ncbi.nlm.nih.gov/substance/488201578
IUPAC Name N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide
INCHI InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)
InChi Key QGZYDVAGYRLSKP-UHFFFAOYSA-N
Canonical SMILES C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
Isomeric SMILES C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=NC=C(C=N3)C(=O)NCCCCCCC(=O)NO
PubChem CID 53340666
分子量 433.5

化学和物理性质

溶解性 DMSO 87 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

相关文档

质检报告COA

请输入批号:


相关技术文章

FAQ
RNA病毒触发信号通路
RNA Viruses Triggered Signal Pathway

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC et al..  (2012)  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma..  Blood,  119  (11):  (2579-89).  [PMID:22262760]
2. Kalin JH, Bergman JA.  (2013)  Development and therapeutic implications of selective histone deacetylase 6 inhibitors..  J Med Chem,  56  (16):  (6297-313).  [PMID:23627282]